Dominant PDX1 deficiency causes highly penetrant diabetes at different ages, associated with obesity and exocrine pancreatic deficiency: lessons for precision medicine.
DPP4 inhibitors
GLP1 receptor agonist
Monogenic diabetes
PDX1
Journal
Diabetes & metabolism
ISSN: 1878-1780
Titre abrégé: Diabetes Metab
Pays: France
ID NLM: 9607599
Informations de publication
Date de publication:
21 Dec 2023
21 Dec 2023
Historique:
received:
27
10
2023
revised:
15
12
2023
accepted:
18
12
2023
medline:
24
12
2023
pubmed:
24
12
2023
entrez:
23
12
2023
Statut:
aheadofprint
Résumé
Heterozygous pathogenic or likely pathogenic (P/LP) PDX1 variants cause monogenic diabetes. We comprehensively examined the phenotypes of carriers of P/LP PDX1 variants, and delineated potential treatments that could be efficient in an objective of precision medicine. The study primarily involved a family harboring a novel P/LP PDX1 variant. We then conducted an analysis of documented carriers of P/LP PDX1 variants, from the Human Gene Mutation Database (HGMD), RaDiO study, and Type 2 Diabetes Knowledge Portal (T2DKP) including 87K participants. Within the family, we identified a P/LP PDX1 variant encoding p.G232S in four relatives. All of them exhibited diabetes, albeit with very different ages of onset (10-40 years), along with caudal pancreatic agenesis and childhood-onset obesity. In the HGMD, 79% of carriers of a P/LP PDX1 variant displayed diabetes (with differing ages of onset from eight days of life to 67 years), 63% exhibited pancreatic insufficiency and surprisingly 40% had obesity. The impact of P/LP PDX1 variants on increased risk of type 2 diabetes mellitus was confirmed in the T2DKP. Dipeptidyl peptidase 4 inhibitor (DPP4i) and glucagon-like peptide-1 receptor agonist (GLP1-RA), enabled good glucose control without hypoglycemia and weight management. This study reveals diverse clinical presentations among the carriers of a P/LP PDX1 variant, highlighting strong variations in diabetes onset, and unexpectedly high prevalence of obesity and pancreatic development abnormalities. Clinical data suggest that DPP4i and GLP1-RA may be the best effective treatments to manage both glucose and weight controls, opening new avenue in precision diabetic medicine.
Identifiants
pubmed: 38141807
pii: S1262-3636(23)00089-7
doi: 10.1016/j.diabet.2023.101507
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
101507Informations de copyright
Copyright © 2023. Published by Elsevier Masson SAS.
Déclaration de conflit d'intérêts
Declaration of Competing Interest Authors declare that they have no competing interests.